Clinical collaboration with BeiGene announced on April 3, 2023 to evaluate the safety and efficacy of Allocetra™, an investigational macrophage-reprogramming...
Updated clinical data for NXC-201, a next-generation CAR-T for multiple myeloma and AL amyloidosis, will be presented in Paris, France...
Favorable feedback following meeting with the U.S. Food and Drug Administration (FDA) allows for planned resubmission of erosive esophagitis new...
ProFound AI Risk offered higher accuracy than Tyrer-Cuzick v8 for all women, regardless of menopausal status, breast density, and family...
-- Approval of VAZKEPA® to Reduce the Risk of Cardiovascular (CV) Events in Adult Statin-Treated Patients at High CV Risk...
Approximately 75 per cent of pet telemedicine appointments can be treated solely through virtual care, without stepping into a clinic Pet...
ROCKAWAY, N.J., April 04, 2023 (GLOBE NEWSWIRE) -- electroCore, Inc. (the “Company”), (NASDAQ: ECOR), a commercial-stage bioelectronic medicine and wellness...
BERLIN and INDIANAPOLIS, April 04, 2023 (GLOBE NEWSWIRE) -- Eckert & Ziegler (ISIN DE0005659700, TecDAX) and a subsidiary of POINT...
Feasibility and safety demonstrated in patients with advanced heart failureSafe maximal dose for continuation into Phase 2 (Proof-of-Concept) identifiedProof for...
Commercial revenue from specialty safety syringe systems is advancing Company to launch its vial draw syringe systems in Q2 2023Launch...
Companies seek compensation for Pfizer’s and BioNTech’s unlicensed use of patented technologies in COVID-19 mRNA-LNP vaccines WARMINSTER, Pa., April 04,...
SOUTH ORANGE, NJ, April 04, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – Nephros, Inc. (Nasdaq: NEPH), a leading water technology...
Patient enrollment to commenceCarlsbad, Calif., April 04, 2023 (GLOBE NEWSWIRE) -- Aurora Spine Corporation (“Aurora Spine” or the “Company”) (TSXV:ASG)...
CAMBRIDGE, Mass., April 04, 2023 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced the appointment of Adam Keeney, Ph.D.,...
Zevra seeks to expand KP1077 clinical program to address multiple rare sleep disorders CELEBRATION, Fla., April 04, 2023 (GLOBE NEWSWIRE)...
Approximately two-thirds of trial patients with Major Depressive Disorder achieving remission following SPL026 treatment sustained remission to six-months Aggregated Remission...
Opportunity to Accelerate Long-Term Organic Growth and Expand Patient AccessCINCINNATI, April 04, 2023 (GLOBE NEWSWIRE) -- Quipt Home Medical Corp....
MELBOURNE, Australia and SAN FRANCISCO, April 04, 2023 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the...
Tactoset cleared by the FDA to be combined with autologous bone marrow aspirate, a core element for regenerative healing Anika...
BOCA RATON, Fla., April 03, 2023 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage immunology company focused on...